Quintrio
Home

Stock overview

BioHarvest Sciences Inc. Common Stock

BHST

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.907 – $1.41
Volume 86,670
Market cap $31M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for BHST.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for BHST.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates

BioHarvest Sciences Inc. (BHST) reported a Q3 loss of $0.15 per share, beating EPS estimates but missing revenue expectations with $7.87 million versus the consensus estimate. The company's stock has declined 66.3% year-to-date, significantly underperforming the S&P 500's 11.3% gain. BHST received a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates

MiNK Therapeutics reported a Q3 loss of $0.5 per share, beating consensus estimates of $0.66 loss by 24.24%. The company posted $0.2 million in revenues, surpassing estimates by 33.33% compared to zero revenues a year ago. However, shares have underperformed the market, down 10.2% year-to-date versus the S&P 500's 9.9% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates

ImmunityBio (IBRX) reported a quarterly loss of $0.10 per share, missing consensus estimates of $0.08, representing a -25% earnings surprise. Revenue of $48.84 million also missed expectations by 19.6%, though it grew from $32.06 million year-over-year. Despite the miss, the stock has surged 336.1% YTD versus the S&P 500's 7.8% gain. The company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.

GlobeNewswire Inc.

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

OTC Markets Group reported the performance of its OTCQX and OTCQB indexes in Q4 2024. The OTCQX Composite Index, OTCQX Billion+ Index, and OTCQX Dividend Index all declined, while the OTCQX Banks Index and OTCQX U.S. Index saw gains. Several companies moved from the OTC markets to major exchanges during the quarter.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.